

## Re: Your request made under the Freedom of Information Act 2000

- 1) How many patients have been treated with biologics or biosimilar products in the last 12 months for the following conditions:

**Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Non-Radiographic Axial Spondyloarthritis

- 2) Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 12 months with the following drugs.

**We don't have a separate cost centre for Rheumatology at BDGH, so the data for this question is for the whole trust (all specialties) with the DRI Rheumatology data in brackets. The report period is Oct 19 to Sep 20.**

- Abatacept [Orencia] **29 (4)**
- Adalimumab [Amgevita] **497 (270)**
- Adalimumab [Humira] **49 (21)**
- Adalimumab [Hyrimoz] **0 (0)**
- Adalimumab [Imraldi] **0 (0)**
- Apremilast [Otezla] **97 (8)**
- Baricitinib [Olumiant] **98 (97)**
- Certolizumab [Cimzia] **0 (0)**
- Etanercept [Benepali] **345 (243)**
- Etanercept [Enbrel] **34 (31)**
- Etanercept [Erelzi] **31 (30)**
- Golimumab [Simponi] **61 (55)**
- Infliximab [Flixabi] **0 (0)**
- Infliximab [Inflectra] **0 (0)**
- Infliximab [Remicade] **13 (6)**
- Infliximab [Remsima] **285 (24)**
- Ixekizumab [Taltz] **7 (7)**
- Rituximab [MabThera] **25 (0)**
- Rituximab [Rixathon] **0 (0)**
- Rituximab [Truxima] **199 (64)**
- Sarilumab [Kevzara] **17 (16)**
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]